Journal article
Urinary β2-microglobulin and disease activity in patients with tubulointerstitial nephritis and uveitis syndrome
Journal of Ophthalmic Inflammation and Infection, Vol.8(1), 24
12/29/2018
DOI: 10.1186/s12348-018-0166-3
PMCID: PMC6311166
PMID: 30594950
Abstract
Background
Urinary β2-microglobulin (Uβ2M) is elevated in tubulointerstitial nephritis and uveitis (TINU) syndrome and has emerged as an important diagnostic tool. This study aims to determine whether Uβ2M correlates with uveitis activity in TINU.
Methods
Retrospective observational case series of nine patients with TINU and ≥ 30 days follow-up. Presenting symptoms, visual acuity, uveitis characteristics, follow-up, Uβ2M, serum creatinine (SCr), urinalysis, and renal biopsy results were collected.
Results
A correlation between Uβ2M and anterior chamber (AC) cell (r = 0.69, 95% CI 0.46–0.84), flare (r = 0.65, 95% CI 0.39–0.81), trended toward a stronger correlation than SCr and AC cell (r = 0.59, 95% CI 0.29–0.79), flare (r = 0.52, 95% CI 0.19–0.75). Uβ2M decreased over 1–2 years while SCr returned to normal within a few months.
Conclusions
Uβ2M correlate with uveitis activity and trend down over the course of TINU. Uβ2M may serve as a useful tool in determining where patients are in their systemic disease course.
Details
- Title: Subtitle
- Urinary β2-microglobulin and disease activity in patients with tubulointerstitial nephritis and uveitis syndrome
- Creators
- Lorraine M Provencher - University of Iowa, Internal MedicineAaron M. Fairbanks - University of Iowa Hospitals and ClinicsMichael D. Abramoff - University of Iowa, Ophthalmology and Visual SciencesNasreen A. Syed - University of Iowa, Ophthalmology and Visual Sciences
- Resource Type
- Journal article
- Publication Details
- Journal of Ophthalmic Inflammation and Infection, Vol.8(1), 24
- Publisher
- SpringerOpen
- DOI
- 10.1186/s12348-018-0166-3
- PMID
- 30594950
- PMCID
- PMC6311166
- ISSN
- 1869-5760
- eISSN
- 1869-5760
- Copyright
- © 2018, Springer Nature
- Grant note
- This work was supported by unrestricted Funds from Research to Prevent Blindness, New York, NY. Michael D. Abràmoff is supported by the Robert C. Watzke Professorship of Ophthalmology and Visual Sciences, Iowa City, IA. Competing Interests: The authors declare that they have no competing interests related to this work. MDA has the following financial interests and consultancy: IDx LLC, Iowa City, IA, founder; IDx LLC, Iowa City, IA, investor (equity interests); IDx LLC, Iowa City, IA, consultant; IDx LLC, Iowa City, IA, president; Gerson Lehrman Group, consultant, expert testimony; iOptics BV, Amsterdam Netherlands, founder; iOptics BV, Amsterdam Netherlands, investor (equity interests); EASDEC invited speaker; EU retina invited speaker; ATA invited speaker; and MICCAI invited speaker. Dr. Abràmoff has the following intellectual property leading to royalties: University of Iowa patents, University of Iowa patent applications, IDx LLC patents, IDx LLC patent applications.
- Language
- English
- Date published
- 12/29/2018
- Academic Unit
- Internal Medicine
- Record Identifier
- 9983761184102771
Metrics
68 File views/ downloads
23 Record Views